Skip to main content
    V

    Volitionrx Ltd (VNRX)

    Official site

    HEALTHCARE • MEDICAL DEVICES • AMEX

    $0.19
    +0.01 (+5.98%)

    Market Cap: $5.38M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    64%(25/39)
    Avg Surprise
    -11.78%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.31
    Range$-0.31 - $-0.31
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$-0.70+55.7%
    60d ago$-0.58+46.6%
    30d ago$-0.58+46.6%
    7d ago$-0.58+46.6%
    Current$-0.31
    Revenue Consensus
    $696150
    Range$462000 - $1M
    5 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.29
    Range$-0.29 - $-0.29
    1 analysts
    Revenue Consensus
    $1M
    Range$745590 - $2M
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.29---
    Sep 26EST
    		-$-0.31---
    Jun 26
    Reported Aug 13
    		$-0.78$-0.68-14.71%Miss+40.5%
    Mar 26
    Reported May 14
    		$-0.97$-0.73-32.88%Miss-1516.7%
    Dec 25
    Reported Mar 31
    		$-0.05$-0.05+2.78%Beat+96.2%
    Sep 25
    Reported Nov 13
    		$-1.06$-1.04-1.92%Miss+24.3%
    Jun 25
    Reported Aug 14
    		$-1.31$-1.00-31.00%Miss+18.1%
    Mar 25
    Reported May 15
    		$-0.06$-0.06+0.00%Beat+97.0%
    Dec 24
    Reported Mar 31
    		$-1.20$-1.07-12.15%Miss-990.9%
    Sep 24
    Reported Nov 14
    		$-1.40$-1.30-7.69%Miss+34.6%
    Jun 24
    Reported Aug 14
    		$-1.60$-1.85+13.51%Beat+42.9%
    Mar 24
    Reported May 13
    		$-2.00$-2.15+6.98%Beat+33.3%
    Dec 23
    Reported Mar 26
    		$-0.11$-0.11+0.00%Beat+15.4%
    Sep 23
    Reported Nov 14
    		$-2.14$-2.47+13.36%Beat+23.6%
    Jun 23
    Reported Aug 15
    		$-2.80$-2.87+2.44%Beat+0.0%
    Mar 23
    Reported May 11
    		$-3.00$-2.70-11.11%Miss-7.1%
    Dec 22
    Reported Mar 15
    		$-0.13$-0.15+13.33%Beat+13.3%
    Sep 22
    Reported Nov 14
    		$-2.80$-2.93+4.44%Beat-7.7%
    Jun 22
    Reported Aug 10
    		$-2.80$-2.87+2.44%Beat-34.6%
    Mar 22
    Reported May 11
    		$-2.80$0.90-411.11%Miss-16.7%
    Dec 21
    Reported Mar 30
    		$-0.15$-0.14-7.14%Miss-36.4%
    Sep 21
    Reported Nov 10
    		$-2.60$-2.07-25.60%Miss-34.7%
    Jun 21
    Reported Aug 11
    		$-2.08$-2.33+10.73%Beat+11.9%
    Mar 21
    Reported May 11
    		$-2.40$-2.27-5.73%Miss+14.3%
    Dec 20
    Reported Mar 22
    		$-0.11$-0.10-10.00%Miss+93.1%
    Sep 20
    Reported Nov 12
    		$-1.93$-2.20+12.27%Beat+3.5%
    Jun 20
    Reported Aug 13
    		$-2.36$-2.45+3.67%Beat-7.3%
    Mar 20
    Reported May 7
    		$-2.80$-1.93-45.08%Miss-16.7%
    Dec 19
    Reported Feb 20
    		$-1.60$-2.20+27.27%Beat-1354.5%
    Sep 19
    Reported Nov 12
    		$-2.00$-2.10+4.76%Beat+28.6%
    Jun 19
    Reported Aug 12
    		$-2.20$-2.27+3.08%Beat+26.7%
    Mar 19
    Reported May 8
    		$-2.40$-2.40+0.00%Beat+29.4%
    Dec 18
    Reported Mar 13
    		$-0.11$-0.13+15.38%Beat+26.7%
    Sep 18
    Reported Nov 7
    		$-2.80$-2.80+0.00%Beat+6.7%
    Jun 18
    Reported Aug 13
    		$-3.00$-3.00+0.00%Beat-15.4%
    Mar 18
    Reported May 10
    		$-3.40$-3.20-6.25%Miss-30.8%
    Dec 17
    Reported Mar 1
    		$-0.15$-0.16+6.25%Beat-25.0%
    Sep 17
    Reported Nov 9
    		$-3.00$-3.00+0.00%Beat-
    Jun 17
    Reported Aug 9
    		$-2.60$-2.80+7.14%Beat-
    Mar 17
    Reported May 11
    		$-2.60$-2.75+5.45%Beat-
    Dec 16
    Reported Mar 10
    		$-0.12$-0.13+7.69%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.07EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-1043.00%
    ROE-730.00%ROIC76.93%
    Financial Health
    Debt/Equity-0.35xInterest Coverage-3.88x
    Current Ratio0.30xQuick Ratio0.30x
    Trading Statistics
    Beta1.17Avg Volume3.08M
    52-Week High$9.6052-Week Low$0.17

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.21
    SMA 20$0.23
    SMA 50$0.37
    SMA 200$2.48
    EMA 10$0.21
    EMA 20$0.24
    EMA 50$0.45
    EMA 200$2.65

    MACD

    Line: -0.06Signal: -0.06Hist: 0.01

    ADX

    ADX: 36.0+DI: 13.8-DI: 33.5

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down96.0
    PSAR$0.21

    Bollinger Bands

    Upper Band$0.29
    Lower Band$0.18
    %B Position4668%(Upper)
    Band Width0.10

    RSI (14-Day)

    Oversold
    25.7

    Momentum Oscillators

    Stoch %K9.1
    Stoch %D5.5
    Williams %R-83.2
    ROC (10d)-19.2%
    Momentum-0.04
    CCI (20d)-152.2
    MFI (14d)24.8

    Volatility Measures

    ATR (14d)$0.03(14.5%)
    StdDev (20d)0.03
    Hist Vol72.9%(High)

    Volume Flow

    VWAP$0.19
    OBV442.0M
    AD Line191.8B
    CMF (20d)-0.101

    Volume Metrics

    Avg Vol (20d)1.9M
    Vol Ratio0.7x
    VWMA (20d)$0.24

    Pivot Points

    R3$0.19
    R2$0.19
    R1$0.18
    Pivot Point$0.18
    S1$0.17
    S2$0.17
    S3$0.17

    Advanced Oscillators

    TSI-49.70
    Ultimate Osc29.0
    KST-359.36

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$398,657$985,076$447,034$627,277$406,688$246,385$194,595$474,522$395,797$168,597$243,973$165,211
    Cost of Revenue$0$0N/A$0$0$0$323,875$0$0$0$362,915$0
    Gross Profit$398,657$985,076$447,034$627,277$406,688$246,385$194,595$474,522$395,797$168,597$243,973$165,211
    Operating Expenses$4.55M$6.33M$5.26M$5.73M$6.70M$5.77M$5.97M$6.34M$7.39M$8.56M$8.97M$8.83M
    R&D$1.80M$2.85M$2.47M$2.29M$2.72M$2.61M$2.59M$3.47M$3.72M$4.63M$4.54M$4.65M
    SG&A$2.21M$2.63M$1.80M$2.48M$2.94M$2.24M$2.13M$1.82M$2.28M$2.25M$2.54M$2.60M
    Operating Income$-4,155,983$-5,348,852$-4,818,054$-5,100,990$-6,297,807$-5,521,720$-5,781,340$-5,868,707$-6,990,419$-8,384,504$-8,740,574$-8,653,055
    Interest Income$163$16$122$160$160$158$313$530$450$8,654$8,337$230
    Interest Expense$1.74M$1.59M$1.07M$873,430$448,661$96,669$92,491$89,456$81,182$77,233$57,999$53,980
    Income Before Tax$-7,315,604$-6,703,557$-6,304,670$-5,409,791$-6,314,400$-5,476,627$-5,788,648$-5,868,578$-7,060,175$-8,540,584$-8,815,613$-8,437,275
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-7,315,263$-6,703,557$-6,302,841$-5,409,791$-6,314,070$-5,476,627$-5,857,227$-5,868,578$-7,060,175$-8,472,005$-8,799,700$-8,453,188
    EBITDA$-4,884,204$-4,411,718$-4,051,436$-3,497,864$-5,222,051$-5,071,850$-5,344,353$-5,325,341$-6,769,012$-8,149,932$-8,402,657$-8,021,065
    EBIT$-5,574,811$-5,116,263$-5,234,213$-4,536,521$-5,865,899$-5,380,116$-5,696,470$-5,779,652$-6,979,443$-8,472,005$-8,765,951$-8,383,525
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about VNRX

    News

    Nasdaq cuts target to USD 13.89 for VolitionRx stock

    Nasdaq has reduced its average one-year target for VolitionRx stock to USD 13.89, a 17.44% decrease, citing a difficult operating profile in Q2 2026 and wide dispersion in analyst expectations. Despite launching its...

    ad-hoc-news.de•10/15/26•Neutral

    Neither party sold shares as VolitionRx (VNRX) retained 284 shares for its commercial chief’s taxes.

    VolitionRx (VNRX) retained 284 shares of its Chief Commercial Officer, Gael Forterre, to cover tax withholding obligations related to the settlement of 687 restricted stock units. Neither Forterre nor VolitionRx sold...

    Stock Titan•10/1/26•Neutral

    No shares were sold as VolitionRx (VNRX) retained 608 COO shares for cancellation to cover taxes.

    VolitionRx Ltd (VNRX) reported that its Chief Operating Officer, Michel Gaetan, had 608 common shares retained by the company for cancellation. This action was taken to satisfy tax-withholding obligations related...

    Stock Titan•10/1/26•Neutral

    VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France

    VolitionRx has released further details and a video about the launch of its DETECSEPS program in France. The program aims to improve sepsis diagnosis and management...

    Moomoo•9/17/26•Bullish

    A €6.3 million French program will test one blood marker to spot sepsis early

    VolitionRx's Nu.Q NETs H3.1 assay has been chosen as the sole biomarker for a €6.3 million French government-funded program, DETECSEPS...

    Stock Titan•9/17/26•Bullish

    VNRX Valuation and Fair Value

    P/E
    -0.1x
    Forward P/E
    20.8x
    PEG
    0.0x
    P/B
    -0.1x
    See GNG's fair value

    VNRX Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -1043.0%
    Net margin
    0.0%
    ROIC
    76.9%
    ROE
    -730.0%
    FCF margin
    -796.8%

    VNRX Competitors

    CompanyTicker
    Scienture Holdings, Inc.SCNX
    Processa Pharmaceuticals IncPCSA
    Longeveron LLCLGVN
    Aptorum Group Ltd Class AAPM
    enVVeno Medical CorpNVNO
    Trinity Biotech plcTRIB
    Sonoma Pharmaceuticals IncSNOA
    Icecure MedicalICCM

    Sector: Healthcare

    VNRX Analyst Ratings

    Consensus
    Buy
    Analysts
    5
    Strong Buy
    1
    Buy
    3
    Hold
    1
    Sell
    0
    Strong Sell
    0

    VNRX Bull Case vs Bear Case

    Bull case

    • VNRX earns a 76.9% return on invested capital.
    • 80.0% of VNRX's analyst ratings are Buy or Strong Buy.

    Bear case

    • VNRX beat EPS estimates in 12.5% of its last 8 reported quarters.
    • VNRX's quarterly revenue changed -2.0% year over year.

    VNRX Earnings: Beat Rate and Next Report

    Beat rate
    1 of 8 quarters (12.5%)
    Average surprise
    -12.2%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.31
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About VNRX

    Does VNRX pay dividends?

    Volitionrx Ltd (VNRX) does not currently pay a regular dividend.

    What is VNRX's market cap?

    Volitionrx Ltd (VNRX) has a market capitalization of $5.38M with a current stock price of $0.19.

    Related stocks

    Sector: Healthcare

    All stocks starting with V

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In